Overview

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to characterize the safety, maximum tolerated dose (MTD) and preliminary efficacy profile of IPI-145 given in combination with rituximab, or bendamustine plus rituximab, to subjects with select relapsed/refractory hematologic malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborator:

Infinity Pharmaceuticals, Inc.

Treatments:

Bendamustine Hydrochloride
Rituximab